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Why Cochrane should prioritise sharing data 
Open sharing is vital for collaboration, innovation, and reproducibility: Cochrane could show 
leadership. 
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Why Cochrane should prioritise sharing data 
Open sharing is vital for collaboration, innovation, and reproducibility: Cochrane could show 
leadership. 
 
Packer1 discusses that the one who submits a research for public good should be ready to receive a 
request for data sharing for examination and re-analysis and tax payers assume that a national 
agency is checking such data and analysis. Here we discuss Cochrane’s practice on data sharing. 
Open science, as endorsed by the G7,2includes sharing data, computer code and materials. 
It is essential for reproducibility, collaboration, and innovation. We support the work of 
Cochrane, but are concerned Cochrane is not sharing all its reviews’ data. These data should 
be fully accessible for re-use by third parties. 
Cochrane, a non-profit private company3 and registered charity, produces and maintains 
systematic reviews in health and social care. Its work is undertaken by a global network of 
thousands of people,4 and its support largely comes from public funding.5Most people 
producing Cochrane reviews are volunteers, not specifically funded for this work6 7and 
Cochrane encourages ‘crowdsourcing’ of work.8-10 
Cochrane Editorial bases help volunteers obtain study reports and manually extract the 
wealth of data needed to generate systematic reviews.11-13Cochrane teams use RevMan 
software14to produce files in standard format (XML), storing information on the studies, 
their methods and results for publication in the Cochrane Library. 
Benefits of sharing extracted data from trials and systematic reviews are well known, as are 
the costs of not sharing.13 15-17 Sharing maximises transparency, reliability of data extraction, 
and syntheses. It improves access to data - saving time and money - and opens new avenues 
of inquiry.18 Sharing is associated with increased citations,19more publications,20 and re-use 
for new purposes.16 
Structured data from Cochrane should be fully accessible for download, re-use and review 
(Box 1). Currently, they are not. Although Cochrane supports transparency initiatives such as 
AllTrials,21 and is explicit about this within its policy,22 it has no similar clear principles on 
opening full access to the data within Cochrane reviews. Cochrane does provide access to 
results data from reviews but, crucially, these cannot be readily re-used; and the available 
information is an incomplete set of the data generating these reviews, comes in a 
technically problematic format and can only be viewed by thosewith access to the full 
content of the Cochrane Library.23-25 
 
Box 1. Structured data and associated metadata 
Reference data 
    - All data from within Cochrane Central Register of Controlled Trials (CENTRAL) 
excluding copyrighted abstracts (so creating OPEN CENTRAL) 
    - All data from within Cochrane Register of Studies (CRS) excluding copyrighted 
abstracts (so creating OPEN CRS) 
    - Links to ‘parent’ study  
    - Links to ‘parent’ reviews 
Study data 
    - Links to ‘child’ references 
    - Links to ‘parent’ reviews 
 Characteristics of studies: 
                   - Methods, participants, interventions, outcomes 
    - Qualitative data on risk of bias 
    - Quantitative data on outcomes 
    - Qualitative and quantitative derived data  
– meta-analysis results, grading of quality of outcomes 
 
Small amounts of Cochrane data have been released with bespoke arrangements for specific 
individuals. This sharing is welcome, but there is a lack of an organisational culture, policy, 
or process regarding data release; there is no appeals process. For example, OpenTrials 
aggregates all accessible documents on all trials in an open database and makes it free for 
public re-use.26 27 Thus far, OpenTrials have been unable to persuade Cochrane to share 
data for re-use. The Trip Database28 is a searchable library of evidence that asked to re-
present structured data from Cochrane but also encountered barriers to access.29 Open 
sharing could foster collaborative ecosystems of digital innovation going beyond academic 
publications, with outputs which might include live, interactive presentations of summaries 
and results of trials produced by teams around the world, interactive decision support tools 
and many more. 
Cochrane’s non-release of data is unlikely to reflect the preferences of funders, publishers, 
the thousands of Cochrane volunteers, participants in trials, or patients. For example, when 
asked, 83% of the members of the Cochrane Individual Participant Data (IPD) Meta-analysis 
Methods Group supported sharing systematic review data via a central repository 
(recognising that the IPD might require some form of moderated access).30 Many funders 
now require that data arising from their grants are shared.31-34 Cochrane volunteer authors 
give tacit consent for use of their work within reviews but may not be aware of the 
restrictions placed on access to the data they worked so hard to prepare.25 This is morally 
and ethically questionable, potentially eroding public trust.16 35 
This issue of Open Science is now pressing, following recent moves by Cochrane to create 
more information and become a hub for systematic review data. This has potential to 
improve evidence and patient care, but while the Cochrane Linked Data Project aims to 
share re-usable data in some form,36 37 as yet, there is no information on how or when this 
will happen.38 39 Furthermore, Cochrane is making efforts towards ‘living’ systematic 
reviews, with updates from data in real-time.40 This is important work, but progress is slow. 
Opening up this work with shared data resources, and in collaboration with the open source 
software community - where all can contribute - would accelerate progress and best reflect 
the culture of collaboration in science. 
Open data offers a transformative, collaborative future for the systematic review 
community. Cochrane has enabled a vast workforce to painstakingly extract information for 
great benefit. Cochrane could act as a hub, harmonising data collected across groups and 
sharing these widely, reflecting the collective funding and volunteer workforce that 
produces them. This could involve the conversion of the morass of free text trial reports into 
machine-readable curated data, in archived, citable, accessible, inter-operable and re-usable 
formats, as set out in the FAIR Principles.41 42 Cochrane could show leadership in supporting 
innovation and open science for clinical trials with full credit to all data extractors before43 
and after review publication44 and, in this way harness greatest broadest impact. This 
reflects the exciting current move towards better use of data to produce digital tools of 
direct value to clinicians, rather than academic publications alone.   
Open data is a route to success and impact in the 21st century. We have raised these issues 
with Cochrane,45 and understand that the organisation is considering whether to commence 
a process of reviewing its approach to sharing data.46 We hope that our setting out the 
benefits of open data is a helpful contribution to open that discussion. 
We appreciate Cochrane must focus on making itself sustainable and that open data sharing 
may be commercially sensitive.47 However, making Cochrane a champion for openness, 
transparency and sharing can only be beneficial for the organisation’s reputation - and 
finances. We encourage Cochrane leadership to create a policy that allows open data 
sharing and to make explicit any concerns they have on open data sharing so that these can 
be resolved. 
 
Box 2. Key Messages 
● Cochrane could lead and set standards for open data sharing from systematic reviews. 
● Availability of data from Cochrane reviews would: 
○ give opportunities for collaboration, innovation, scientific replication, novel 
research and clinical decision making. 
○ reduce the considerable waste of the current duplication of effort in systematic 
reviewing. 
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